Apogee Therapeutics, Inc.
US ˙ NasdaqGM ˙ US03770N1019

SecurityAPGE / Apogee Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership133,193 shares
Latest Disclosed Value $ 10,053,408
Barclays Plc reports 79.26% decrease in ownership of APGE / Apogee Therapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 133,193 shares of Apogee Therapeutics, Inc. (US:APGE) valued at $10,053,408 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 642,316 shares of Apogee Therapeutics, Inc.. This represents a change in shares of -79.26% during the quarter. The current value of the position is $11,213,519 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F APOGEE THERAPEUTICS COM 03770N101 133,193 -509,123 -79.26 10,053 -60.61 0.0024
2026-03-31 2025-09-30 13F/A-3 APOGEE THERAPEUTICS COM 03770N101 642,316 33,494 5.50 25,519 -3.49 0.0055
2026-03-19 2025-09-30 13F/A-2 APOGEE THERAPEUTICS COM 03770N101 365,046 -243,776 21,443 0.0057
2025-11-12 2025-09-30 13F APOGEE THERAPEUTICS COM 03770N101 642,316 33,494 25,519 0.0055
2026-02-27 2025-06-30 13F/A-2 APOGEE THERAPEUTICS COM 03770N101 608,822 110,197 22.10 26,441 41.94 0.0061
2025-08-14 2025-06-30 13F/A-1 APOGEE THERAPEUTICS COM 03770N101 608,822 110,197 26 0.0061
2025-08-13 2025-06-30 13F APOGEE THERAPEUTICS COM 03770N101 608,822 110,197 26 0.0020
2026-03-17 2025-03-31 13F/A-1 APOGEE THERAPEUTICS COM 03770N101 498,625 21,865 4.59 18,629 -13.75 0.0053
2025-05-15 2025-03-31 13F APOGEE THERAPEUTICS COM 03770N101 498,625 21,865 19 0.0053
2026-03-19 2024-12-31 13F/A-1 APOGEE THERAPEUTICS COM 03770N101 476,760 111,714 30.60 21,597 0.72 0.0061
2025-02-13 2024-12-31 13F APOGEE THERAPEUTICS COM 03770N101 476,760 111,714 22 0.0061
2026-03-31 2024-09-30 13F/A-2 APOGEE THERAPEUTICS COM 03770N101 365,046 287,243 369.19 21,443 600.49 0.0057
2024-11-19 2024-09-30 13F/A-1 APOGEE THERAPEUTICS COM 03770N101 365,046 287,243 21 0.0057
2024-11-15 2024-09-30 13F APOGEE THERAPEUTICS COM 03770N101 365,046 287,243 21 0.0017
2026-03-23 2024-06-30 13F/A-1 APOGEE THERAPEUTICS COM 03770N101 77,803 41,157 112.31 3,062 25.71 0.0009
2024-08-14 2024-06-30 13F APOGEE THERAPEUTICS COM 03770N101 77,803 41,157 3 0.0009
2026-03-24 2024-03-31 13F/A-1 APOGEE THERAPEUTICS COM 03770N101 36,646 2,590 7.61 2,435 156.05 0.0008
2024-05-15 2024-03-31 13F APOGEE THERAPEUTICS COM 03770N101 36,646 2,590 2 0.0008
2026-03-25 2023-12-31 13F/A-1 APOGEE THERAPEUTICS COM 03770N101 34,056 34,056 952 0.0003
2024-02-15 2023-12-31 13F APOGEE THERAPEUTICS COM 03770N101 34,056 34,056 1 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.